PharmaSGP Holding SE

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: DE000A2P4LJ5
EUR
29.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Dec'18
Net Sales
118.84
101.10
85.82
65.34
63.25
62.57
60.59
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
118.84
101.10
85.82
65.34
63.25
62.57
60.59
Raw Material Cost
28.28
26.10
25.13
15.32
12.29
10.43
10.30
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
8.03
7.34
6.91
4.69
3.77
2.04
1.70
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
4.38
4.68
2.19
0.71
0.10
0.18
0.01
Selling and Distribution Expenses
63.06
50.38
42.04
34.36
36.07
29.91
30.95
Other Expenses
-1.24
-1.20
-0.91
-0.54
-0.39
-0.22
-0.17
Total Expenditure (Excl Depreciation)
91.34
76.48
67.17
49.68
48.36
40.34
41.25
Operating Profit (PBDIT) excl Other Income
27.5
24.6
18.700000000000003
15.700000000000001
14.9
22.200000000000003
19.3
Other Income
1.41
1.15
0.31
0.19
0.13
0.20
0.21
Operating Profit (PBDIT)
38.62
35.23
28.54
19.43
15.50
22.84
19.94
Interest
4.38
4.68
2.19
0.71
0.10
0.18
0.01
Exceptional Items
1.21
0.63
-1.36
-0.94
-0.76
0.00
0.00
Gross Profit (PBDT)
90.56
75.00
60.69
50.02
50.96
52.15
50.29
Depreciation
9.41
9.30
9.19
3.57
0.49
0.40
0.39
Profit Before Tax
26.04
21.89
15.80
14.21
14.15
22.26
19.54
Tax
6.50
5.50
3.85
3.52
3.51
5.56
4.80
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
19.54
16.40
11.95
10.69
10.64
16.71
14.73
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
19.54
16.40
11.95
10.69
10.64
16.71
14.73
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
19.54
16.40
11.95
10.69
10.64
16.71
14.73
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
31.96
39.75
31.10
22.20
11.51
95.58
84.37
Earnings per share (EPS)
1.65
1.37
1.0
0.89
0.89
1.39
1.23
Diluted Earnings per share
1.65
1.37
1.0
0.89
0.89
1.39
1.23
Operating Profit Margin (Excl OI)
23.4%
24.52%
22.19%
23.97%
23.53%
35.54%
31.92%
Gross Profit Margin
29.83%
30.85%
29.12%
27.21%
23.14%
36.21%
32.88%
PAT Margin
16.44%
16.22%
13.93%
16.36%
16.82%
26.7%
24.31%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Dec 2024 is 17.51% vs 17.83% in Dec 2023

stock-summary

Consolidate Net Profit

YoY Growth in year ended Dec 2024 is 18.90% vs 36.67% in Dec 2023

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2024 is 9.09% vs 20.92% in Dec 2023

stock-summary

Interest

YoY Growth in year ended Dec 2024 is -6.38% vs 113.64% in Dec 2023

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2024 has fallen from Dec 2023

Compare Annual Results Of PharmaSGP Holding SE With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(EUR)
Change(%)
Net Sales
118.84
69.67
49.17
70.58%
Other Operating Income
0.00
0.00
0.00
Total Operating income
118.84
69.67
49.17
70.58%
Raw Material Cost
28.28
54.84
-26.56
-48.43%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
8.03
26.04
-18.01
-69.16%
Power Cost
0
0
0.00
Manufacturing Expenses
4.38
1.11
3.27
294.59%
Selling and Distribution Expenses
63.06
21.31
41.75
195.92%
Other Expenses
-1.24
-1.06
-0.18
-16.98%
Total Expenditure (Excl Depreciation)
91.34
92.65
-1.31
-1.41%
Operating Profit (PBDIT) excl Other Income
27.49
-22.98
50.47
219.63%
Other Income
1.41
3.17
-1.76
-55.52%
Operating Profit (PBDIT)
38.62
-10.00
48.62
486.20%
Interest
4.38
1.11
3.27
294.59%
Exceptional Items
1.21
-108.17
109.38
101.12%
Gross Profit (PBDT)
90.56
14.83
75.73
510.65%
Depreciation
9.41
9.81
-0.40
-4.08%
Profit Before Tax
26.04
-129.08
155.12
120.17%
Tax
6.50
-18.58
25.08
134.98%
Provisions and contingencies
0
0
0.00
Profit After Tax
19.54
-125.67
145.21
115.55%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
19.54
-125.67
145.21
115.55%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
19.54
-125.67
145.21
115.55%
Equity Capital
0
0
0.00
Face Value
1.00
0.00
0.00
Reserves
31.96
461.84
-429.88
-93.08%
Earnings per share (EPS)
1.65
-7.18
8.83
122.98%
Diluted Earnings per share
1.65
-7.18
8.83
122.98%
Operating Profit Margin (Excl OI)
23.40%
-32.98%
0.00
56.38%
Gross Profit Margin
29.83%
-171.19%
0.00
201.02%
PAT Margin
16.44%
-180.37%
0.00
196.81%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 11.88 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 17.51% vs 17.83% in Dec 2023

Annual - Consolidate Net Profit
Consolidate Net Profit 1.95 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 18.90% vs 36.67% in Dec 2023

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 3.72 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 9.09% vs 20.92% in Dec 2023

Annual - Interest
Interest 0.44 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is -6.38% vs 113.64% in Dec 2023

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 23.40%
in Dec 2024

Figures in %
stock-summary

YoY Growth in year ended Dec 2024 has fallen from Dec 2023